Laumas Sandeep 4/A

What Happened
Laumas Sandeep, a director of Unicycive Therapeutics, received two restricted stock unit (RSU) awards on 2026-05-14 totaling 126,300 RSUs (84,200 + 42,100). The grants are reported as derivative acquisitions at $0.00 per share (aggregate reported value $0), meaning these are stock awards subject to vesting rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-14; Form 4 filed as an AMENDED report on 2026-06-15 (appears to be filed after the transaction date).
• Reported acquisition: 84,200 RSUs (footnote F1) and 42,100 RSUs (footnote F2) at $0.00 per share.
• Vesting (per footnotes):
  • F1 (84,200 RSUs): 11,694 shares vested upon grant; remaining 2,339 RSUs vest monthly over 31 months beginning June 1, 2026.
  • F2 (42,100 RSUs): 17,542 shares vested upon grant; remaining 3,508 RSUs vest monthly over 7 months beginning June 1, 2026.
• Shares owned after transaction: not disclosed in this filing.
• Filing status: AMENDED Form 4 filed 2026-06-15 for transactions dated 2026-05-14 (note the filing date is after the transaction date).

Context
RSU grants are awards that convert to common shares according to the stated vesting schedule; they do not represent an immediate cash purchase or sale by the insider. Such grants are common as compensation or retention tools and do not, by themselves, indicate buying or selling intent.